Next-Generation Sequencing for Characterizing Drug Resistance-Conferring Mycobacterium tuberculosis Genes from Clinical Isolates in the Ukraine

Author:

Daum L. T.1,Konstantynovska O. S.2,Solodiankin O. S.3,Liashenko O. O.2,Poteiko P. I.2,Bolotin V. I.3,Hrek I. I.2,Rohozhyn A. V.2,Rodriguez J. D.1,Fischer G. W.1,Chambers J. P.1,Gerilovych A. P.3

Affiliation:

1. Longhorn Vaccines and Diagnostics, San Antonio, Texas, USA

2. Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine

3. National Scientific Center Institute for Experimental and Clinical Veterinary Medicine, Kharkiv, Ukraine

Abstract

ABSTRACT The Ukraine ranks among the top 20 countries with the highest number of multidrug-resistant (MDR) and extensively drug resistant (XDR) Mycobacterium tuberculosis cases in the world. However, little is known of the genetic diversity, i.e., resistance signatures, in clinical isolates from this region. We analyzed seven of most prevalent MDR/XDR antibiotic resistance-conferring genes from clinical isolates ( n = 75) collected from geographically diverse Ukrainian oblasts and the southern Crimean peninsula. Genomic analysis revealed that 6 (8%) were sensitive, 3 (4%) were resistant to at least one antibiotic but were not MDR, 40 (53%) were MDR, and 26 (35%) were XDR. The majority of isolates (81%) were of the Beijing-like lineage. This is the first study to use next-generation sequencing (NGS) of clinical isolates from the Ukraine to characterize mutations in genes conferring M. tuberculosis drug resistance. Several isolates harbored drug resistance signatures that have not been observed in other countries with high-burden tuberculosis. Most notably, the absence of inhA gene promoter mutations, a diversity of mutation types in the rpoB resistance-determining region, and detection of heteroresistance provide a broader understanding of MDR/XDR from this area of the world.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Reference41 articles.

1. Global TB Programme, WHO. 2015. Use of high burden country lists for TB by WHO in the post-2015 era. Strategic and Technical Advisory Group for TB, World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/global_report/high_tb_burdencountrylists2016-2020.pdf.

2. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis

3. Hindustantimes. 24 March 2017. Drug-resistant TB cases rising in India: Lancet. Hindustantimes, New Delhi, India. http://www.hindustantimes.com/health-and-fitness/drug-resistant-tb-cases-rising-in-india-Lancet/story-LnL3IEsqPdrv3buYWn0K5I.html.

4. World Health Organization. June 2016. Ukraine—tuberculosis profile. World Health Organization, Geneva, Switzerland. https://extranet.who.int/sree/Reports?op=Replet&name=%2FWHO_HQ_Reports%2FG2%2FPROD%2FEXT%2FTBCountryProfile&ISO2=UA&LAN=EN&outtype=html.

5. HIV and MDR-TB in Ukraine: news from a hazardous MDR-TB and HIV site;Granich R;Int J Tuberc Lung Dis,2008

Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3